Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of K0706 in Parkinson's Disease
NCT02970019Phase 1Completed
- Sponsor
- Sun Pharma
- Start
- Mar 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing K0706 with Placebo (2 arms). Primary endpoint: Adverse events at 4 weeks. Started Mar 2017; status: completed.
02
Drugs
vodobatinib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02970019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970019.